Jake Leach

“Today we reported second quarter revenue growth of 13% compared to the second quarter of 2025 and organic revenue growth of 12%. We carried forward solid demand from the first quarter for Dexcom CGM globally as we benefited from broader access and share gains across several core markets as well as patient categories.”

“Before we begin, I'd like to take a moment to recognize Kevin Sayre, who is not on the call today and, as many of you know, has taken a temporary medical leave.”

“Yeah, we were incredibly excited to receive the approval for 15-day, and we've got the internal team very focused on getting this product launched, and so we, as you mentioned, one of the things we're doing to ready ourselves for launch is working with all of our pump partners to ensure there's compatibility for the…”

“The 15-day review, right, we mentioned that we'd submitted it on the last call, so we're basically towards the tail end of that review. We've had a great interactive, you know, review with the FDA.”

“So, we are very excited about transitioning our G6 AID users over to G7 once those pump partners have compatibility. That’s coming very rapidly. And we really think it's going to be important for those users to be able to access the benefits of G7.”